Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Bioorg Med Chem ; 17(23): 8040-7, 2009 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-19875300

RESUMO

The cytotoxicity showed by 1b, an interesting representant of the title compounds, for HT-29 human colon cancer cells (CI(50) value of 1.95 x 10(-7)M) has been related to the induced cell death at the G2 phase and not to DNA damage. This compound promotes the degradation of components of the G2/M checkpoint machinery, in particular cdc2, Cyclin B1 and Wee1, which represents a novel mechanism of cytotoxicity. Degradation of Wee1 seems to be mediated by proteasome activity but degradation of cdc2 has to occur through a different mechanism. The activity of 1b on G2 cell cycle components suggests that tumor cells that are arrested in G2/M by anticancer drugs like cisplatin could be targeted by compound 1b, increasing the apoptosis induction, and that their optimized analogs might be useful in the treatment of colon cancer through combination therapies with cisplatin or other anticancer drugs that affect the cytoskeleton integrity such as taxol and taxotere. SAR studies with compounds obtained by manipulation of the N(2) and C(4)-functional groups and the C(6)-chain of compound 1b have confirmed the importance of these structural features in the in vitro antitumor activity. Fused oxazolidine derivatives as compound 5 were inactive, and the lack of activity found in the replacement of the C(4)-lactam by a cyanoamine function, as in compounds 8-10, could be explained considering that their all-syn relative configuration makes them too stable to generate alkylating iminium species.


Assuntos
Proteínas de Ciclo Celular/metabolismo , Sobrevivência Celular/fisiologia , Fase G2/fisiologia , Isoquinolinas/síntese química , Pirazinas/síntese química , Transdução de Sinais/fisiologia , Apoptose/fisiologia , Proteínas de Ciclo Celular/antagonistas & inibidores , Sobrevivência Celular/efeitos dos fármacos , Células HT29 , Humanos , Isoquinolinas/química , Isoquinolinas/farmacologia , Espectroscopia de Ressonância Magnética , Pirazinas/química , Pirazinas/farmacologia , Espectroscopia de Infravermelho com Transformada de Fourier , Relação Estrutura-Atividade
2.
Bioorg Med Chem ; 16(19): 9065-78, 2008 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-18799316

RESUMO

The in vitro antitumor potential of novel pyrazino[1,2-b]-isoquinoline-4-ones that contain a half portion of significant natural products was explored in three cancer cell lines: MDA-MB 231 human breast carcinoma, A-549 human lung carcinoma, and HT-29 human colon carcinoma. In general, these compounds show mid to low muM GI(50)s, but LC(50)s over 100 microM with the exceptions of compounds 3b and 31 that are moderately toxic in all cell lines, while compound 4a is highly toxic and selective for HT-29 cells with LC(50) values in the high nanomolar range. Experiments directed to elucidate possible mechanisms of action with compounds 3a, 29, and 31 showed that compound 3a is able to efficiently induce apoptosis triggered directly from the G2/M phase of cell cycle, while compounds 29 and 31 are potentially cytostatic agents that induce the G1/S arrest of cell cycle. All three compounds do not act through DNA damage, since they do not activate this signaling at the level of sensors, transducers, and executers. Furthermore, the apoptosis induction of 3a is not mediated by activation of pro-apoptotic kinases JNK and p38 or by activation of AKT.


Assuntos
Apoptose/efeitos dos fármacos , Ciclo Celular/efeitos dos fármacos , Citostáticos/farmacologia , Dano ao DNA/efeitos dos fármacos , Isoquinolinas/farmacologia , Pirazinas/farmacologia , Adenocarcinoma/metabolismo , Adenocarcinoma/patologia , Apoptose/fisiologia , Ciclo Celular/fisiologia , Divisão Celular , Linhagem Celular Tumoral , Citostáticos/síntese química , Dano ao DNA/fisiologia , Fase G1 , Fase G2 , Células HT29 , Humanos , Concentração Inibidora 50 , Isoquinolinas/síntese química , Proteínas Quinases JNK Ativadas por Mitógeno/metabolismo , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patologia , Proteínas Proto-Oncogênicas c-akt/metabolismo , Pirazinas/síntese química , Fase S , Relação Estrutura-Atividade , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...